Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance

Medpace Holdings IncTrade
Vanguard Tax Managed Fund FTSE Developed Markets ETFTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Medpace Holdings Inc trades at $600.99 (market cap $16.90B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.27. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.

MEDPVEA
Market Cap
$16.90B
Sector
Technology
52-Week High
$620.59$72.89
52-Week Low
$393.42$58.19
Enterprise Value
$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Vanguard Tax Managed Fund FTSE Developed Markets ETF

VEA trades at $73.22, up 0.99% with a bullish technical outlook supported by moving averages. The ETF provides diversified exposure to developed international markets excluding the U.S. Recent institutional activity shows mixed sentiment with both new positions and reductions. VEA's low expense ratio of 0.03% and competitive dividend yield remain key advantages for international diversification.

Outlook remains positive for long-term investors seeking international exposure, though near-term technical indicators show potential overbought conditions. Key risks include currency fluctuations and global economic uncertainty. The ETF's cost efficiency and broad diversification support its appeal despite mixed institutional positioning.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About Vanguard Tax Managed Fund FTSE Developed Markets ETF

The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VEA